黑色素瘤市场：KOL 洞察

本报告调查全球黑色素瘤市场，并提供了市场概述，包括已上市的治疗方法、研发产品线趋势和未来前景。

目次

执行摘要

处理演算法

研究目的

上市済み治疗法

• 概要
• 免疫疗法
  • Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals)
  • Opdualag (nivolumab/relatlimab; Bristol Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)

BRAF/MEK抑制剂

• 概要
  • 主要见解摘要
  • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
  • Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche)
  • Braftovi/Mektovi (encorafenib/binimetinib; Pfizer)

溶瘤病毒/免疫刺激剂

• 概要
  • Imlygic (T-VEC/talimogene laherparepvec; Amgen)

肿瘤浸润淋巴球（TIL）细胞疗法

• 主要见解摘要
  • Amtagvi (lifileucel; Iovance Biotherapeutics)

研发线疗法

免疫检查点抑制剂

• 概要
  • 主要见解摘要
  • BAL/BOT (balstilimab/botensilimab; Agenus)
  • Libtayo ([cemiplimab)]/fianlimab; Regeneron)
  • Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.)

病灶内药物

• 概要
  • 主要见解摘要
  • RP1 (vusolimogene oderparepvec; Replimune)
  • Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen)
  • CMP 001 (vidutolimod; Regeneron)

重组免疫刺激剂

• 概要
  • 主要见解摘要
  • IO 102 (IDOlong)/IO 103 [PD-L1 peptide vaccine]; IO Biotech)
  • mRNA-4157 (V940 [personalised cancer vaccine]; Moderna)

下一代 BRAF/MEK 抑制剂

• 概要
  • 主要见解摘要
  • LXH 254 (naporafenib; Erasca)
  • HL-085 (tunlametinib; KeChow Pharma)

免疫细胞毒性/T淋巴球刺激剂

• 概要
  • 主要见解摘要
  • Kimmtrak (tebentafusp; Immunocore/Medison Pharma)
  • IIMC-F106C (brenetafusp; Immunocore)

组蛋白去乙酰化酶（HDAC）抑制剂

• 概要
  • 主要见解摘要
  • Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International)

中/早期研发线

• 主要见解摘要
  • 专家强调癌症免疫治疗的前景广阔的前沿：B7-H3、双特异性抗体和新组合引领潮流

附录

新闻

This report provides a comprehensive analysis of the current and future landscape of melanoma therapies. It delves into insights from key opinion leaders (KOLs) across the US, Australia, and Europe, focusing on the evolving roles of established treatments like Opdivo and Yervoy and emerging therapies. Gain an understanding of the latest clinical data, ongoing trials, and the impact of biosimilars on treatment accessibility. This report also explores the challenges and opportunities in personalised treatment strategies, offering a detailed view of how the melanoma treatment paradigm is expected to shift in the coming years.

Key questions answered:

• What are the preferred first- and subsequent-line melanoma treatments?
• How do current and pipeline therapies compare in efficacy and tolerability?
• What must pipeline therapies demonstrate to become the top choice?
• How will the use of melanoma therapies change by patient segment and preference?
• What efficacy and tolerability must pipeline products show to compete?
• Which promising pipeline candidates will impact current market players?
• How will melanoma treatment evolve for each therapy line?

Key brands covered in this report:

List of Companies:

Table of Contents

Executive summary

Treatment algorithm

Research objectives

Marketed therapies

• Overview
• Immunotherapies
  • Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals)
  • Opdualag (nivolumab/relatlimab; Bristol Myers Squibb)
  • Keytruda (pembrolizumab; Merck & Co.)

BRAF/MEK inhibitors

• Overview
  • Key insights summary
  • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
  • Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche)
  • Braftovi/Mektovi (encorafenib/binimetinib; Pfizer)

Oncolytic viruses/immunostimulants

• Overview
  • Imlygic (T-VEC/talimogene laherparepvec; Amgen)

Tumour infiltrating lymphocyte (TIL) cell therapy

• Key insights summary
  • Amtagvi (lifileucel; Iovance Biotherapeutics)

Pipeline therapies

Immune checkpoint inhibitors

• Overview
  • Key insights summary
  • BAL/BOT (balstilimab/botensilimab; Agenus)
  • Libtayo ([cemiplimab)]/fianlimab; Regeneron)
  • Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.)

Intralesional agents

• Overview
  • Key insights summary
  • RP1 (vusolimogene oderparepvec; Replimune)
  • Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen)
  • CMP 001 (vidutolimod; Regeneron)

Recombinant immunostimulants

• Overview
  • Key insights summary
  • IO 102 (IDOlong)/IO 103 [PD-L1 peptide vaccine]; IO Biotech)
  • mRNA-4157 (V940 [personalised cancer vaccine]; Moderna)

Next-generation BRAF/MEK inhibitors

• Overview
  • Key insights summary
  • LXH 254 (naporafenib; Erasca)
  • HL-085 (tunlametinib; KeChow Pharma)

Immunologic cytotoxicity/T lymphocyte stimulants

• Overview
  • Key insights summary
  • Kimmtrak (tebentafusp; Immunocore/Medison Pharma)
  • IMC-F106C (brenetafusp; Immunocore)

Histone deacetylase (HDAC) inhibitor

• Overview
  • Key insights summary
  • Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International)

Mid/early-stage pipeline

• Key insights summary
  • Experts highlight promising frontiers in cancer immunotherapy: B7-H3, bispecifics, and novel combinations lead the way

Appendix

• KOL details
  • KOLs from the Australia/USA
  • KOLs from Europe

News